Our genetic experiments with FIt1 inhibition in cancer cells and the depletion experiments with VEGFR2 antibody allowed us to differentiate between the contribution of FLT1 and VEGFR2 to PARPi resistance in breast cancer. The gene discussed is KDR; the disease is cancer.